Name | bromohexine hydrochloride |
Synonyms | bisolvon bromessina BROMHEXINE HCL bisolvonhydrochloride BROMHEXINE HYDROCHLORIDE bromohexine hydrochloride 2-amino-n-cyclohexyl-3,5-dibromo-n-methyl-benzylaminhydrochloride 2-amino-n-cyclohexyl-3,5-dibromo-n-methylbenzylaminehydrochloride 2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine hydrochloride 2-AMINO-3,5-DIBROMO-N-CYCLOHEXYL-N-METHYLBENZY-LAMINE HYDROCHLORIDE N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloride n-(2-amino-3,5-dibromobenzyl)-n-methylcyclohexylamine hydrochloride 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline hydrochloride 2-amino-3,5-dibromo-n-cyclohexyl-n-methyl-benzenemethanaminmonohydrochlo |
CAS | 611-75-6 |
EINECS | 210-280-8 |
InChI | InChI=1/C14H20Br2N2.ClH/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17;/h7-8,12H,2-6,9,17H2,1H3;1H |
InChIKey | UCDKONUHZNTQPY-UHFFFAOYSA-N |
Molecular Formula | C14H21Br2ClN2 |
Molar Mass | 412.59 |
Melting Point | 240-244°C |
Boling Point | 441.5°C at 760 mmHg |
Flash Point | 220.8°C |
Solubility | Soluble in water (<1 mg/ml at 25 °C), ethanol (5 mg/ml at 25 °C), methanol (1:50), a |
Vapor Presure | 3.37E-08mmHg at 25°C |
Appearance | powder |
Color | White to Light Beige |
Maximum wavelength(λmax) | ['307nm(Decane)(lit.)'] |
Merck | 14,1391 |
BRN | 4848376 |
Storage Condition | Sealed in dry,Room Temperature |
Sensitive | Sensitive to light |
MDL | MFCD00056626 |
Physical and Chemical Properties | melting point 240-244°C |
Use | Used as an expectorant |
Hazard Symbols | Xn - Harmful |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 2 |
RTECS | XS9950000 |
HS Code | 29215990 |
This product is N-methyl-N-cyclohexyl-2-amino -3, 5-dibromobenzylamine hydrochloride. Based on the dry product, the content of C14H20Br2N2 • HCl should be between 98.0% and 102.0%.
take this product, precision weighing, plus ethanol dissolution and quantitative dilution of about 20% per lml solution, according to UV-visible spectrophotometry (General 0401 ), the absorbance was measured at a wavelength of 249nm, and the absorption coefficient was 262 to 278.
take this product, precision weighing, add methanol to dissolve and dilute to make a solution containing about 2.5mg per 1 ml, as a test solution; Take the appropriate amount of precision, A solution containing 5ug per 1 ml was prepared as a control solution by quantitative dilution with methanol. According to the chromatographic conditions under the content determination item, respectively inject l0ul of the test solution and the control solution into the liquid chromatograph to record the chromatogram to twice the retention time of the main component peak. If there is a chromatographic peak consistent with retention time of impurity I in the chromatogram of the test solution, the peak area shall not be greater than 0.75 times (0.15%) of the main peak area of the control solution, other single impurity peak area shall not be greater than 0.5 times (0.1%) of the main peak area of the control solution, and the sum of each impurity peak area shall not be greater than 1.5 times (0.3%) of the main peak area of the control solution.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
measured by high performance liquid chromatography (General 0512).
silica gel bonded with eighteen alkyl silane as filler; Phosphate buffer (potassium dihydrogen phosphate l. Add 900ml water to dissolve, adjust the pH value to 7.0 with 0.5mol /L sodium hydroxide solution, dilute to 1000ml with water, and shake to obtain)-acetonitrile (20:80) as mobile phase; the column temperature was 40°C and the detection wavelength was 245Nm. Appropriate amounts of the reference substance for impurity I and the reference substance for Bromhexine hydrochloride were dissolved in methanol and diluted to prepare a mixed reference substance solution containing about 5ug and 2.5mg per 1 mL respectively. Lol was injected into the liquid chromatograph and the chromatogram was recorded, the degree of separation between the impurity I peak and the Bromhexine peak should be greater than 2.0.
take an appropriate amount of this product, weigh it accurately, add methanol to dissolve and dilute it quantitatively to make a solution containing about 0.5mg per lml, and use it as a test solution, and take 10 u1 accurately, injection into the liquid chromatograph, record the chromatogram; Take the appropriate amount of Bromhexine hydrochloride reference, accurately weigh, add methanol to dissolve and quantitatively dilute to make a solution containing about 0.5mg per 1 ml, and determine with the same method. According to the external standard method to calculate the peak area, that is.
expectorant.
sealed storage.
This product contains Bromhexine hydrochloride (C14H20Br2N2 • HCl) should be 93.0% ~ 107.0% of the label amount.
This product is white tablet.
with Bromhexine hydrochloride.
8mg
sealed storage.
Introduction | Bromhexine hydrochloride is a mucolytic agent, which can directly act on the bronchial glands and promote the release of lysosomes of mucus secreting cells, the differentiation and lysis of mucopolysaccharide fibers in sputum, sputum dilution, easy to cough. Clinically, it is mainly used for acute and chronic bronchitis, asthma, bronchiectasis, emphysema, especially for white sputum expectoration difficulties and critical emergencies caused by sputum extensive obstruction of small bronchi. Bromhexine hydrochloride tablets, solutions, aerosols, injection, freeze-dried powder injection, infusion and other dosage forms. |
preparation | 2.0g of 2-amino -3, 5-dibromobenzaldehyde, 1.2g of N-methyl cyclohexylamine is dissolved in 20ml of methanol, and 4g of tetraisopropyl titanate is slowly dropped into the reaction solution under stirring at room temperature, and after adding, the reaction is continued at room temperature for 5 hours; 0.3g of sodium borohydride was added to the reaction solution in portions, and the reaction was stirred at room temperature for 2H. The reaction was complete by TLC. After the reaction, add 20ml of water to the reaction solution to quench the reaction, precipitate a large number of solids, filter, filter cake washed with ethyl acetate for 3 times, combine filtrate and wash, extract with ethyl acetate to obtain organic phase, the organic phase was washed sequentially with sodium carbonate solution and saturated brine. 5ml of 6N hydrochloric acid was added dropwise to the organic phase at room temperature under stirring, and the mixture was stirred for 3H for crystallization. A white solid was obtained by filtration, recrystallized from ethanol and dried to obtain 2.3g of Bromhexine hydrochloride. Yield: 78%. |
biological activity | Bromhexine HCl is a drug that treats Cough of hard sputum by dissolving it. |
Use | this strain is based on the active ingredient proposed in the medicinal plant duckbill flower (hyonidine) the structure of the synthesis of a new type of mucus soluble expectorant, has a strong role in dissolving phlegm. Can make sputum mucopolysaccharide fiber differentiation and lysis, can also inhibit the synthesis of mucopolysaccharides, so that sputum sialic acid (one of the acidic mucopolysaccharides) content reduced, thereby reducing the viscosity of sputum, there are Nausea of the expectorant effect after oral administration, so that sputum is easy to cough, so that the respiratory tract is smooth. It is clinically used for the treatment of acute and chronic bronchitis, asthma, bronchiectasis and emphysema, especially for the difficulty of expectoration of white phlegm, and the shortness of breath caused by extensive obstruction of small bronchi by sputum. Adverse Reactions: taking this product occasionally Nausea, stomach discomfort, reduction or discontinuation can disappear. A small number of patients with temporary elevated serum transaminase. Patients with gastric ulcer should be used with caution. The toxicity of this product is very small. used as expectorant This product is a new type of mucolytic expectorant, which can differentiate and split the mucopolysaccharide fibers in sputum, reduce the viscosity of sputum and increase the secretion, thus thinning the sputum, easy to cough, make respiratory tract unobstructed, relieve symptoms |
production method | There are a variety of process routes. One of them is o-toluidine as raw material, first bromination to produce 2, 4-dibromo-6-toluidine, and acetic anhydride reaction to acetylated amino to produce N,N-diacetyl-2, 4-dibromo-6-methylaniline; The amino group is protected and then brominated again to form N, n-diacetyl-2, 4-dibromo-6-bromomethylaniline; condensation with N-methylcyclohexylamine to N, n-diacetyl-2, 4-dibromo-6-(N-methyl) cyclohexylamine methylaniline. Finally, hydrochloric acid is used to hydrolyze the acetyl group and salt to obtain the finished product. |
category | toxic substances |
toxicity grade | poisoning |
Acute toxicity | oral-rat LD50: 6000 mg/kg; Oral-mouse LD50: 4800 mg/kg |
flammability hazard characteristics | toxic nitrogen oxides, bromide and hydrochloric acid fumes emitted by thermal decomposition |
storage and transportation characteristics | warehouse ventilation and low temperature drying |
fire extinguishing agent | water, foam, sand, carbon dioxide, dry powder |